PAQ Therapeutics secures $39 million in Series B financing to advance its KRAS degrader PT0253, co-led by MRL Ventures Fund and Bayland Capital.

May 07, 2025•8 months ago

Amount Raised

$39 Million

Round Type

series b

BurlingtonTherapeuticsBiotechnologyHealth Care

Investors

Sherpa Health PartnersBio Track CapitalLav FundJohnson & Johnson Innovation – Jjdc Inc.Bayland CapitalMrl Ventures Fund

Description

PAQ Therapeutics, a biotechnology firm, announced its completion of a $39 million Series B funding round. The financing is aimed at advancing their lead asset PT0253 into further clinical development, following the dosing of the first patient in a Phase 1 trial. The round was co-led by MRL Ventures Fund and Bayland Capital, with investments from several notable firms. These funds will also support further development of PAQ's additional assets.

Company Information

Company

PAQ Therapeutics

Location

Burlington, Massachusetts, United States

About

PAQ Therapeutics is a biotechnology company pioneering a new approach to restoring heath and curing disease through autophagy, the body’s most versatile mechanism for natural cellular degradation. With our ATTEC (autophagosome-tethering compound) technology, we are developing a novel class of small molecule degraders capable of binding a diverse array of substrates to the autophagy pathway including proteins, aggregates, lipids, organelles and pathogens. PAQ’s research advances in this important new class of degradation therapies have the potential to fundamentally transform drug discovery and development.

Related People

3 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends